Award
NIH Reporter #1R43AG094353-01A1
Restoring AD-related neuronal dysfunction with a neuroprotective peptide
Recipient
NEUREXIS THERAPEUTICS, INC.
Award Amount
$484,929.00
Ceiling
$484,929.00
Awarded
September 17, 2026
Identifier
1R43AG094353-01A1
NIH awarded a grant to NEUREXIS THERAPEUTICS, INC. for developing a neuroprotective peptide tatCN19o aimed at restoring neuronal function and cognitive abilities in Alzheimer's disease models, with a project period from September 2026 to September 2027 and funding of approximately $485,000.
Description
This NIH SBIR grant supports the development and testing of the neuroprotective peptide tatCN19o to restore synaptic plasticity and cognitive functions impaired by Alzheimer's disease (AD). The project involves testing the peptide in mouse models to evaluate its potential to restore long-term potentiation (LTP) and improve learning and memory.